Editas Medicine Inc. (EDIT) Stock Price Today & Analysis

Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
About Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
FAQ
- Download the Gotrade app from the App Store or Google Play.
- Create an account and complete KYC.
- Make a deposit.
- Search for the code "EDIT", then tap "Trade".
- Tap the "Buy" button.
- Enter the amount you want to buy. You have two options:
- Buy EDIT by number of shares.
- Buy fractional shares in dollars, starting from $1.
- Swipe up to confirm your order—done!
- Compare valuation (e.g., P/E, P/S) against historical averages or competitors.
- Review revenue and earnings growth.
- Check margins and cash flow.
- Evaluate business outlook and the company's position within its industry.





